InvitroCue
Singapore, Singapore· Est.
Personalized cancer testing using patient‑derived organoids for drug‑selection guidance.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Personalized cancer testing using patient‑derived organoids for drug‑selection guidance.
Oncology
Technology Platform
Proprietary 3‑D scaffolding technology that enables patient‑derived organoid culture for high‑throughput drug screening and functional precision oncology.
Opportunities
Expansion of functional precision oncology services into global cancer centers and deeper integration with pharmaceutical drug‑development pipelines.
Risk Factors
Regulatory approval for companion‑diagnostic use, adoption barriers in clinical workflows, and competition from other PDO platform providers.
Competitive Landscape
Competes with Hubrecht Organoid Technology, Cellenkos, and Recursion Pharma; differentiates through its proprietary 3‑D scaffolding and strong academic partnerships in Asia.